BIRAC - BIG Report - 17 Sept - 2015
BIRAC - BIG Report - 17 Sept - 2015
BIRAC - BIG Report - 17 Sept - 2015
The Journey
A simple, yet accurate serological test for TB is an urgent unmet need. Through its BIG grant, Achira has developed a multiplexed,
antigen detection test for TB using novel aptamer reagents. These nucleic acid based reagents are specific enough to pick up two
different TB antigens that are secreted by the bacillus. The aptamer reagents have been ported onto Achira’s proprietary microfluidics
platform where they are currently undergoing clinical performance evaluation. Achira has benefitted from the BIG grant through funding
for a high-impact, high-risk project and also through access to the larger biotech community in India and timely advice from the review
committees at BIRAC and CCAMP. Once validated, we believe that this test will be an important addition to the battle against TB
The Journey
Affigenix Biosolutions Private Limited is on its way in meeting the milestones of DBT-BIRAC BIG 3 grant project titled “Development
of pan reactive Trypsin resistant antibodies for industrial applications” in association with C-CAMP , BIG partner. We currently have
clients from Biopharma industries who are using our anti-Trypsin antibodies developed from the proof-of-concept studies and have
been successful in generating revenues. In case of Affigenix, BIRAC seed to budding entrepreneurs have indeed started to bloom early
and bear fruits and we are confident of anchoring our roots in India and branch into the world market soon.
The Journey
The BIG project “To demonstrate Proof of Concept for a novel, non-invasive exosome-based screening cum diagnostic kit for multiple
cancers utilizing patient derived biofluids” is related to development of a liquid biopsy test to detect and diagnose cancer(s) at molecular
level. For this, we aim to assemble the technology into a kit for non-subjective, non-expensive and single test based cancer(s)diagnosis.
The technology should reduce patient’s travel time, omits the need of highly skilled medical professionals, and enhances accessibility
of oncodiagnostics to the larger population. Our goal is to implement it for early cancer screening purposes once the proof-of-concept
is ready. BIG funding has been instrumental in creating further grant opportunities for me and I formed a company, established multiple
National, International collaborations.
The Journey
We (Amnivor Medicare Pvt. Ltd.) have developed a procedure for isolation of collagen with higher thermal stability from fish scales of
fresh water origin and prepared collagen based downstream products for wound healing and tissue engineering applications in a cost
effective way. This source is safer i.e. less chance of disease transmission and economical as compared with bovine sources. In our
country most of these products are imported and costly, and therefore not affordable to even middle class people. Our indigenously
developed technology can improve health care delivery in a cost-effective way and hence serve mass population specifically poor
sectionof the society. The proposed collagen source will also facilitate to overcome the religious barrier. The BIRAC has supported us to
set up pilot scale plantand arranged training on entrepreneurship skill development.
The Journey
Monoclonal antibodies (MAbs) have been widely used as treatments for a range of indications, including oncology, and infectious
diseases. Manufacturing costs now represent 20 –25 % of annual sales. The downstream processing costs are 50 – 80 % of the total costs.
There is an urgent need for alternative strategies to purify MAbs to reduce the costs. We purified trastuzumab, directly from cell culture
media using crystalline technology and compared it with soluble with regard to its purity, biosimilarity and efficacy. The current strategy
can be used to eliminate costly Protein A column to reduce the cost of manufacturing.
The Journey
Diabetes drugs are insulin sensitizers and/or insulin releasers, e.g. metformin, glitazones, and glipizide, tolbutamide, followed by the
incretin activators or DPP-IV inhibitor gliptin drugs. The BIG project explores a new class of N-oxide drugs which are postulated to
interact with the -cell signaling pathway to activate insulin release and also increase the islet density and pancreatic cells mass. A proof
of concept study of BLNO was carried out in insulinogenic cell lines and Wistar rats. BIG funding was helpful to carry out the early
explorations. Now we have POC results in hand on a novel first in class lead drug for type 2 diabetes.
Cellzyme Biotech
Rajkumar Rajagopal(Call 4)
The Journey
CELLZYME BIOTECH, a Coimbatore based start-up was founded by Dr. Rajkumar Rajagopal in 2013. Antibiotics are manufactured at -50°C
and require harmful organic solvents and high amounts of alkali leading to the regulatory hurdles due to the formation of undesired
impurities. Our BIG idea stems on addressing the unmet need of USFDA regulated pharmaceutical industries. Our proposed enzymatic
process is cost-effective, greener and safer. Our central focus in BIRAC-SPARSH project is to develop an iron rich protein hydrolysate from
rice bran to address the nutritional requirements of infants and young mothers. In addition to the financial support, BIRAC supported us
with mentoring as BIRAC-IGNITE fellowship to attend IGNITE 2015 at Judge Business School, University of Cambridge.
The Journey
Biotechnology Ignition Grant of BIRAC has enabled us in realizing a handheld “imaging” based malaria diagnostic device which fully
automates the conventional microscopy based analysis- the gold standard method of malaria detection. The product consists of a
custom designed portable digital microscope augmented with dedicated microfluidic lab-on-chips to enable process automation, as
well as, cost-effective implementation. This self-operable in-vitro point-of-care quantitative diagnostic device requires only a drop-of-
blood, and examines lakhs of cells on a single-cell level within a span of five minutes at such an affordable cost-per-test that it could be
used by people living in rural areas as well.
GeNext Genomics
Supriya Kashikar (Call 2)
The Journey
GeNext Genomics (GNG) Pvt. Ltd. team is validating a unique target and developing a novel therapeutic in the form of a new biological
entity for the cure of tuberculosis. “Dying of tuberculosis: The earth is suffocating- Swear to make them cut me open, so that I won’t be
buried alive- Fredrich Chopin”. TB kills two million individuals every year, infecting one third of world’s population. A novel and effective
molecule will not only cure the disease but also have huge social impact. BIRAC-BIG has provided a niche for us to take up high risk
project and deliver. The mentorship program provided by C-CAMP helped us nurture our entrepreneur journey.
Gowrishankar W (Call 3)
The Journey
BIRAC is the main facilitator to bring my dream of a wearable dialysis device to reality through its BIG grant, bringing my simple idea
into a proof of concept in a BIG way. BIRAC has been the magical “open sesame” in getting BIG incubation support, angel investments,
network with doctors and patients. It has provided me with a bigger launchpad, lifting my project to higher levels with all stake holders.
BIRAC shall surely usher in a biggest relief for renal patients throughout the world to lead a normal.
The Journey
IndioLabs has developed a novel semi-automated biopsy device, integrating two unique technologies. BioScoop™ is a novel needle
designed to pierce through and sample soft tissue with a single needle. Simultaneously, the BxSeal™ technology injects a controlled
volume of hemostatic agent into the tissue cavity, thereby immediately stabilizing any internal hemorrhaging from the tissue. Together,
they offer a novel, simple, safe and cost-effective solution for liver biopsy.
The need of a device solution was identified during clinical immersion at the Stanford India Biodesign Programme at AIIMS. Indio Labs
was funded under the BIG scheme to further develop the tissue resection technology and needle characterization/calibration. The
mentors at C-CAMP helped from all aspects in developing the relevant connections and made our entrepreneurial journey a smooth one.
Intraosseous Device
The Journey
‘Ozyn-D’ a novel intraosseous device allows immediate vascular access through long bones in patients having difficult intravenous access
in clinical emergencies. Also, a huge requirement exists in defence segment. It is acompact, lightweight, affordable and easy-to-use even
by paramedics in resource constrained settings. Available as a pre-packaged, ready-to-insert, sterile disposable device, it becomes non-
reusable after single insertion. Protected by the PCT application (patent filed) it has undergone third party biocompatibility testing.
With ‘Make in India’ approach the development has been supported by BIRAC through the BIG. Having completed the in-human cadaver
study at AIIMS, New Delhi it is now ready for First-in-Human (FIH) clinical trial.
The Journey
Using BIRAC-BIG support, Jeevtronics has developed a proof-of-concept for a life saving defibrillator with built-in generator, audio-
ECG (easier to interpret vs. Display ECG) and 4 times more affordable. Two new patents were filed during the BIG phase. Novel power
electronics thus developed has enabled achievement of 4 times lower price. This will work even in rural India, where electricity is not
available for 24 hours/ day. Audio ECG will enable relatively lower skilled personnel to operate this device. This will help improve the
defibrillator to bed ratio in an ICU (presently at 1:50 vs. 1:3 in UK).
The Journey
In SITALOGICS we have a mission to develop innovative biomaterial and regenerative technologies that are cost effective in India. We
are an integrated developer and manufacturer of regenerative bio-materials. We aim to become a world player in five year through our
proprietary cell-interactive biomaterial technologies capable of multiple applications in life science including medical research tools,
drug development and therapeutics Company is focused on translational process towards commercialization of biomedical devices for
wound care, orthobiologic bone graft substitute, biologic haemostat devices apart from research and development efforts for advanced
devices for cellular therapy and tissue engineering We will soon manufacture, formulate, research, develop, process, refine, import,
export, wholesale and/or retail trade in medical devices, Bio Implants, Health Care Products and Tissue Engineering.
The Journey
Currently there is great demand for low cost environment friendly raw material for 3D printing industry in India. Our technology focuses
on developing 3D printable bio-based filaments wherein the formulation and processing characteristics have been optimized. Further,
the developed printable filament will meet requirements such as, biocompatibility and reduced material and process cost. Currently, we
are fine-tuning the various biomaterial formulations and their extrusion parameters. Progress has been made in developing printable
filaments. The BIG award from BIRAC has enabled us immensely to conduct innovative research on this particular technology and we are
indebted for this invaluable financial assistance.
The Journey
Certain important orchid hybrids, viz., Aeridovanda Shiv Sidhu, Holcanthera MS Swaminathan, Renantanda Prof. G.J. Sharma, Renantanda
Kebisana Shija, Renantanda Momon Shija, etc. have been synthesised and registered with the Royal Horticultural Society, London by
Dr. Rajkumar Kishor. The ongoing project, under Biotechnology Ignition Grant (BIG) of BIRAC, focuses on selection of elite clones of the hybrids
and micropropagation for commercial cultivation. It also involves production of secondary hybrids using the above mentioned hybrids as
potential parents. This shall ensure a new range of breeds for future. Orchid hybrids of purely Indian origin shall definitely be novel and there is
high chance of establishing and controlling their market both nationally and internationally. This may help the local growers and entrepreneurs
avail new and surplus planting materials continuously.
The Journey
The project is focussed on developing a standardized reeling and degumming protocol for Muga silk for eventually braiding and swaging
them into needles of appropriate size to make a complete surgical suture. The technological gap in degumming and braiding of wild
varieties of silk fibers are the major issues that the present innovation addresses. Besides the financial support to materialize our
idea, BIRAC has helped us in overcoming the communication and knowledge gap between industry, academia, regulatory bodies and
the market through several workshops and training programs. These programs have helped us in planning the course correction of
the current project and encouraged us to transcend the myopic vision of academic research and focus on developing actual bench
side products.
The Journey
We have demonstrated aPoC for detection of Cardiac Markers (eg hFAbP), using MEMS Microcantilevers, that are released in the blood
after a person has a heart attack. We are now on-track to build a Point-of-Care instrument that can help a Doctor in determining whether
the patient with chest-pain is actually undergoing a heart attack or not. The instrument can be deployed at even Rural Hospitals &
it can be used by a nurse with results in 10 mins. Impact of myocardial infarction on our society is huge, in terms of loss of life and
incapacitation. Our innovation will have a game changing and positive impact on the society, and also on the economic life of our
populace. With BIRAC support we could demonstrate the proof of concept of our innovative idea.
The Journey
We have developed a technology for overproduction of 2,3-butanediol (BDO) using synthetic biology approach. BDO is a platform
chemical with wide application ranging from pharmaceuticals, fuels to rubber industry. Even though it has huge market potential,
India does not have indigenous technology for BDO production. Therefore, we aimed at developing cost effective technology for BDO
production using synthetic biology route for Indian market. It was not very easy to scale up and standardize the whole process but help
by BIRAC in both mentoring and providing monetary help has boosted us to reach our goal on time.
The Journey
The innovation pursued in this project was aimed at addressing the ever increasing menace of drug resistance in gastrointestinal
nematodes of dairy by way of developing a fungal spore formulation guided by an innovative gene expression profile and a unique
delivery device in the form of jaggery tablets. Due to drug resistance, farmers are tempted to use excess drugs that secrete in the milk
which can be controlled with this innovation. BIRAC has been of exceptional assistance in helping me give shape to my thoughts by more
than one ways including fund, guidance, networking and encouragement.
The Journey
SBPL deployed the grant to develop & synthesize “Custom designed Measles viruses” which in-turn helped us to produce SBPL-0100
which kills a wide range of cancer cells without causing toxicity to non-cancerous cells. If successfully launched, SBPL-0100 would be
India’s first “Targeted Cancer therapy” and available at costs lesser than mABs therapies.
We have developed “Active Virosome Technology” platform useful for producing vaccines against viral diseases& used it to produce a
novel vaccine agent (SBPL-0200) for Dengue. SBPL has also produced world’s first VLP vaccine (SBPL-0500) for Measles and shown that
it can induce anti-measles immunity. SBPL-0500 has potential to be useful to vaccinate infants (age 4 to 9 months) which cannot be
vaccinated using current Measles vaccine. We thank DSIR & DBT GOI, The BMGF, USA and ICICI Bank.
The Journey
In India particularly, terminal heart disease is a huge issue even affecting younger population. Hence the need for Artificial Heart over a
long life span is there especially that can withstand wear and tear.
BIRAC support under BIG has enabled giving practical form to the “In use repairable artificial heart” and the patent filing for it. Animal
study being worked out with the BIG support. Physical experiment and Animal experiment facilities at IIT Kharagpur; STEP IIT Kharagpur
gives the infrastructure for the development.
The Journey
Shilps Sciences is a life science and nano-tech company founded in December 2013 with the goal of bringing advancements in
nanotechnology to healthcare. We are developing an Atomic Force Microscope to detect mechanical parameters of cells at the nanometer
scale and use this as a biomarker for metastatic potential in cancer. We have also developed novel microfluidics for single cell analysis.
The goal is to use this for investigating cell heterogeneity, with implications in drug screening, cell based therapies and companion
diagnostics. The company has benefitted from BIRAC’s BIG program and sponsorship for Ignite, a Cambridge entrepreneurship workshop.
The Journey
The innovation is a hardware software co-designed mobile app for real time noninvasive diagnostic imaging of dermatoses. At an initial
phase, the theoretical concepts to model the multispectal optical interactions with various wounds have been conceived. Construction
of multispectral image database for various wounds is under process. The outcome of the product enables real time in situ functional
characterization of dermatoses, avoiding biopsy procedure. The product helps paramedics reach out to resource constrained areas,
facilitating patient comfort centric point-of-care diagnosis. We are based in Kharagpur, incubated at STEP-IIT Kharagpur, and financially
supported by the BIRAC-BIG grant locally through the KIIT-TBI, Bhubaneswar.
The Journey
Sohum is a unique device & system solution to do mass screening of newborns for hearing loss in resource-poor settings to prevent
speech loss. In India, hearing impairment goes undiagnosed till the child is about 4 years. By then, it is too late for the care cycle to be
effective. This leads to speech loss, impaired communication skills, possible mental illness and unemployment. Sohum is a noninvasive,
safe technology to screen neonates for hearing impairment with high sensitivity and specificity in resource-limited settings. It uses
brainstem auditory evoked response (BAER) technology which is gold standard, in an innovative way with an easy-to-use interface
designed specifically for use in developing countries scenario. BIRAC supported Sohum through BIG scheme which helped us refine key
features of Sohum and design refined specification.
String Bio
Ezhil Subbian (Call 3)
The Journey
Imagine a clean world that we would be proud to leave behind for our kids. String’s solution brings us closer to this reality. We are
developing processes to capture methane, largely from waste, into everyday products. Everyday products from plastic cups to
high performance polymers like stents and sutures. Our goal is to enable sustainable cycles for managing waste by using it to make
biodegradable polymers.
Funded by the BIG project from BIRAC, over the course of the last year, we have developed IP protected biocatalysts, fermentation
processes and downstream purification technologies to enable this solution.
The Journey
Swasti Agro and Bioproducts Pvt. Ltd. builds disease resistance in pomegranate against bacterial blight. This has huge positive
environmental impact since toxic chemicals are eliminated. Farmers get predicted, higher yields and more profits. Preliminary results
on sixteen crops grown in India suggest a potential for yield increase of Rs. 15000 cr. per annum.
Initial work on this innovative idea was possibly based only on alchemy of ignorance and amnesia. With BIRAC support we developed
scientific basis, and proof of concept. Development of strong data on mechanism of action was instrumental in attracting serious
investors. Networking opportunities provided much needed connections.
The Journey
The idea is to develop a novel herbal formulation which when administered orally and/or applied topically at the site of injury will
solve coagulation disorders in thousands of people who are suffering from Hemophilia, Thrombocytopenia and different types of
Hemorrhages. It is predicted that the world drugs market for preventing haemorrhages will generate $13.5bn in the year 2017. The
grant has provided the platform from where we can provide the society with a drug that will facilitate in reducing the bleeding diathesis
in people suffering from blood loss. This journey wouldn’t have initiated without the grant provided by BIG BIRAC as this was like a
backbone to an idea that will rise to entrepreneurship.
The Journey
Theramyt’s technology platforms are focused on development of series of novel biomolecules and improved biologics that constitutes
a long term product pipeline. Our target is to alter fucosylation of antibody Fc region to create Biobetter molecules with enhanced
Antibody dependent cellular cytotoxicity (ADCC). The product is expected to provide new treatment options with reduced drug dosage.
The BIG project through BIRAC has helped us to start our R&D program as well as allowed us to incubate at CCAMP, Bangalore. The
support system at CCAMP and through BIRAC has helped us in technical evaluation of our research ideas and refinement of strategy to
achieve specific goals in fairly short period of time. We have already filed multiple provisional patents related to our product and platform
development technologies. We aim to take these novel biologics from bench to manufacturing scale and finally to global market.
The Journey
Innovative materials and methods to create environments that can promote functional cell/ tissue growth in vivo and in vitro has a range
of medical applications including regenerative medicine, drug screening and implantable devices. Our BIG project was to develop of a
novel biomaterial class through assembly of molecular building block- ‘legos’ with tunable material property and functions that can
form the base of the ‘technology pyramid’ of tissue engineering. With BIG, it was possible for us to take the first step into the path of
translational research. Besides funding, BIRAC’s guidance taught us the importance of collaboration with end-users and an awareness of
aspects such as toxicology, ethical and regulatory issues, health economics and clinical trial design that builds the path from the bench
to the bed-side.
The Journey
Fibre lasers are the next generation of high power lasers useful for material modification and surface micro-machining. Unilumen
Photonics has modified this technology for use in surgical applications, such as tissue photo-ablation for prostrate surgery and retinal
photo-coagulation. The lasers are available in both infra-red and visible wavelengths. In addition, pulsed fibre lasers can be synchronized
through a method of injection locking to an external trigger signal. Synchronized pulsed lasers find applications in fields as diverse as
optofluidics lab-on-chip diagnostics and in super-resolution microscopy.
The Journey
There are numerous challenges in the quality, logistics and economics of food analysiswith significant rejection rates and losses in the
export market. Barefeet Analytics aims to address this by providing innovative, reliable and cost efficient solutions for pesticide residue
and contaminant analysis from food. Using laser desorption ionization mass spectrometry methods developed for pesticide analysis,
large numbers of samples can be analyzed rapidly – about 20 times the throughput at about one fifth of the cost of existing methods.
Support from the BIRAC BIG scheme is enabling the development of POC and field trials for analysis from milk.
The Journey
Simple cost effective, efficient, reliable, beta thalassemia carrier detection kit has been developed, requiring no equipment and electricity,
suitable for field application. Validation of the kit in field application is being established with the help of BIRAC BIG grant. Every year
about one lakh thalassemia major children are born all over the world and ten thousand in India alone. The thalassemia children need
blood transfusion every three weeks and their life span is no more than 30 years. The family suffers in distress and helplessness and
country has huge financial burden. The kit aims at thalassemia free society.
The Journey
With BIG support, Vitas Pharma undertook research on a novel class of compounds that target DNA replication in bacteria. The team has
identified a lead series of compounds with in vitro activity against highly resistant Gram negative clinical strains and has established
proof of- concept in the animal model. Further studies to establish the safety of the series are underway. The company has been approved
for a follow-on BIPP Grant. A successful drug emerging from this research will significantly reduce the burden of multidrug resistance and
provide physicians with a novel therapy to treat infections. BIG Grant has allowed us to accelerate our research and was a key factor in
our accessing external funding.
The Journey
We are designing an improved mechanical heart valves that are meant to replace heart valves damaged by infections and ageing and
have more space, reduce possibility of infective complications & paraprosthetic leaks. We estimate a 35% to 115% increase in effective
orifice area. The innovation will have immense societal impact as over 600K patients globally and 40K Indian suffer heart valve disease.
Importantly, 25% patients are small adults or young children who remain the dominant focus of our development. I had considered this
concept design over 10 yrs ago, and along the way I tried to get research organisations to undertake development. That did not work
out. I tried rope in the only Indian heart valve manufacturer to undertake this development, that too did not succeed. With the BIG grant
the much delayed journey started.
The Journey
Transducer-less fetal monitors unlike conventional cardiotocographs is a novel approach to promotecontinuous monitoring of high
& medium risk pregnancies. The alarming rate of stillbirths in India isgreater than the sum of malaria & AIDS related deaths together.
Motivation for the project is anaffordable, portable, non-invasive & easy to use solution for the primary & home care segment. The
first BIG grant from BIRAC has catalysed our idea into a proof-of-concept development. This is nowbeing engineered for pilot market
introduction. This also started us on an entrepreneurial journey by registering “Pradin Technologies Pvt Ltd”.
The Journey
Through this project we identified two industries viz., Oil Palm and Silk reeling industry. Of the total raw silk produced in India (26,480
MT), only 25% is used for silk production, while remaining 75% is discarded as waste. India produces 50,000 M, for every Kg of oil, 3.45 Kg
of waste is generated. Wastes from both these industries have been used to develop High Value Low Volume products such as Omega-3
fatty acids, & Low Value High Volume products like poultry feed, aqua feed, etc. The collaboration with BIRAC and their BIG Partner has
helped us to scale up the innovation and convert it into a commercially viable products. The handholding and the mentorship provided
was a key behind the success of this project.
The Journey
The simple single plane design of the ‘Bhattacharjee ring’ redefines the way pupil is expanded during cataract surgery in eyes which
do not dilate with medications. It paves the way for machine manufacture of the device, translating into reduced costs to the patient
and health care system. The rings are made of 5-0 (0.1 mm) nylon andcan be inserted and removed through a 0.9 mm incision which no
device has been able to achieve. BIRAC through the BIG funding is assisting validation of the concept through multicenter global trials
and development of the ‘Truly Continuous Ring’, ‘Delivery Systems’ & ‘Expandable Ring’.
G.M. Biotech
Susmita Ghosh (Call 1)
The Journey
G.M. Biotech have innovated an animal free, antibody free reagent development platform technology that can be used for detection of
protein markers. Our first product in pipeline is an acute myocardial infarction detection kit based upon earliest cardiac marker H-FABP.
The novel platform technology also enabled us to develop a new instrument-free format of diagnostics that can be practiced in any
healthcare set-up, rural or urban. Since our kit will detect heart attack within 1-2 hrs after the onset, it will aid in much earlier medical
intervention and save more lives. Grant from BIRAC aided us launching this high risk project in a systematic manner and also helped us
building a self-sufficient R&D laboratory.
40 1 Enzymatic maceration of mango pulp to Codon Dr. Archana Centre for Cellular and Molecular
produce quality wine Biosciences Thakur Platforms (C-CAMP), Bangalore
Pvt. Ltd.
41 2 Fibre lasers for photoselective tissue Unilumen Mr. Anil Prabhakar Centre for Cellular and Molecular
ablation Photonics Platforms (C-CAMP), Bangalore
Pvt Ltd
42 2 Testing the feasibility of Nano magnetic Nurture Earth Dr. Seshgiri Centre for Cellular and Molecular
disc based ablation of Cancer cells in vitro R&D Pvt. Ltd. Raghukumar Platforms (C-CAMP), Bangalore
43 2 Establishing and Validating a novel drug GeNext Mrs. Supriya Centre for Cellular and Molecular
target in mycobacterium tuberculosis Genomics Kashikar Platforms (C-CAMP), Bangalore
Pvt Ltd
44 2 Industrial application of a novel cancer InvivoD Dr. Pradip Sinha Centre for Cellular and Molecular
drug screening method Solutions Private Platforms (C-CAMP), Bangalore
Limited
45 2 Development of Fucose Knock out Theramyt Dr. Maloy Ghosh/ Centre for Cellular and Molecular
technology platform in CHO S cell line for Biologics Pvt Ltd Ms. Kavitha Iyer Platforms (C-CAMP), Bangalore
improved Biotherapeutics Rodrigues
46 2 Development and Validation of Gene Dr. Yashoda - Centre for Cellular and Molecular
Delivery System for Novel Model Organisms Ghanekar Platforms (C-CAMP), Bangalore
47 2 A Yeast based system for protein expression Dr. Vinod Nayak - Centre for Cellular and Molecular
and metabolic engineering Platforms (C-CAMP), Bangalore
48 2 Synthetic biology for overproduction of Butacell Research Dr. Nidhi Adlaka Centre for Cellular and Molecular
2,3-butanediol Pvt. Ltd. Platforms (C-CAMP), Bangalore
49 2 Value added products such as Mr. Srinivas - Centre for Cellular and Molecular
nutraceuticals,poultry feed, aqua feed from Bandlamori Platforms (C-CAMP), Bangalore
the wastes/byproducts of palm oil mills and
silk reeling industries
50 2 Developing Novel Lactic Acid Bacteria Dr. Swetha - Centre for Cellular and Molecular
Antimicrobial Interventions to Improve Morey Platforms (C-CAMP), Bangalore
Food Safety and Shelf-Life
51 2 Development Of Low Cost High Shirdi Sai Dr. Munishwar N Centre for Cellular and Molecular
Performance Immobilized Lipases For Nutraceuticals Gupta Platforms (C-CAMP), Bangalore
Intersterification Of Oils Andfats To Produce Pvt. Ltd
Healthy Fats
52 3 Novel, Percutaneous Soft Tissue Biopsy Indio Labs Dr. Siraj Bagwan Centre for Cellular and Molecular
System with assisted Hemostasis Pvt. Ltd. Platforms (C-CAMP), Bangalore
53 3 Hand-held Imaging Flow Cytometer for Dr. Sai Siva - Centre for Cellular and Molecular
Quantitative Diagnosis of Malaria Gorthi Platforms (C-CAMP), Bangalore
References:
https://www.sbir.gov/about/about-sbir
http://www.israelbusiness.org.il/financialassistance/rdfound
http://erawatch.jrc.ec.europa.eu/erawatch/opencms/information/country_pages/il/
supportmeasure/support_0021http://erawatch.jrc.ec.europa.eu/erawatch/opencms/information/country_pages/il/supportmeasure/support_0021
http://www.spring.gov.sg/Nurturing-Startups/Pages/technology-enterprise-commercialisation-scheme.aspx
http://deshpande.mit.edu/grants-resources
http://www.research-in-germany.org/en/research-areas-a-z/biotechnology/programmes-and-initiatives/go-bio.html
http://www.bio-economy.net/bioeconomy/member_states/germany/index_germany.html
http://www.ft.com/cms/s/0/f4109fae-40df-11e5-b98b-87c7270955cf.html
http://www.economist.com/news/business/21584307-new-book-points-out-big-role-governments-play-creating-innovative-businesses